The FDA has approved prasugrel (Effient, Eli Lilly/Daiichi Sankyo) to lower the risk of blood clots from forming in patients who undergo angioplasty to unblock a clogged coronary artery. If blood platelets clump around the procedure site, clots can form and can lead to heart attack, stroke, and death.
The drug’s labeling will include a boxed warning alerting physicians that the drug can cause significant, sometimes fatal, bleeding. Prasugrel should not be used in patients with active pathological bleeding, a history of transient i schemic attacks, stroke, or an urgent need for surgery, including coronary artery bypass graft surgery.
For more information on prasugrel, please see this month’s Drug Forecast column on page 417.
Source: FDA, July 10, 2009